Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst James Quigley has maintained an Equal-Weight rating on Kymera Therapeutics (NASDAQ:KYMR) but reduced the price target from $37 to $24.
November 13, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on Kymera Therapeutics but lowered the price target from $37 to $24, indicating a potential downside compared to the previous target.
The reduction in price target by a major analyst like Morgan Stanley suggests a reassessment of Kymera Therapeutics' future performance or market position, which could lead to a negative investor sentiment and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100